	US 11,981,957 B2
	Methodology to identify biomarkers relevant to neurons in the brain by using non-invasive nasal biopsy
Akira Sawa, Baltimore, MD (US); Koko Ishizuka, Baltimore, MD (US); YeeWen Candace Wu, Baltimore, MD (US); Youjin Chung, Amherst, NY (US); and Nao J. Gamo, Baltimore, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Aug. 21, 2018, as Appl. No. 16/107,246.
Claims priority of provisional application 62/548,267, filed on Aug. 21, 2017.
Prior Publication US 2019/0078149 A1, Mar. 14, 2019
Int. Cl. C12Q 1/6827 (2018.01); A61B 10/02 (2006.01); C12Q 1/6883 (2018.01); G16B 40/10 (2019.01)

CPC C12Q 1/6827 (2013.01) [A61B 10/02 (2013.01); C12Q 1/6883 (2013.01); C12Q 2539/10 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G16B 40/10 (2019.02)]

5 Claims

1. A method of diagnosing increased risk of schizophrenia or biopolar disorder in a human subject comprising:

obtaining single olfactory neurons by a non-invasive brush swab of the subject's olfactory epithelium, wherein neuronal identity is validated by positive expression of OMP;

analyzing the single olfactory neuron by single cell RNA molecular analysis to determine expression NEUROD1, GSK3β and CRMP1;

analyzing the single olfactory neuron by single cell molecular analysis to determine phosphorylation of DISC1; and

detecting a decreased expression of NEUROD1, increased expression of GSK3β and CRMP1, and a decrease of phosphorylation at Serine 713 of DISC1 compared to normal controls; and

diagnosing the subject with decreased expression of NEUROD1, increased expression of GSK3β and CRMP1, and a decrease of phosphorylation at Serine 713 of DISC1 with increased risk of schizophrenia or biopolar disorder.